Estados financieros detallados de TransCode Therapeutics, Inc. (RNAZ): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.68, RNAZ presenta beneficios negativos (P/E no significativo) y un ROE del -58.08%. La capitalización bursátil es de $2M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | $42470 | $98606 | $516746 | $534857 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | -$42470 | -$98606 | -$516746 | -$534857 | 0 |
| I+D | $82532 | $226309 | $284459 | $2.8M | $10.2M | $12.3M | $9.6M | $13.4M |
| Generales y Administrativos | $301464 | $230556 | $442145 | $3.4M | $8.3M | $6.6M | $5.5M | $5.8M |
| Gastos Operativos | $384518 | $456865 | $726604 | $6.1M | $18.6M | $18.9M | $15.1M | $28.0M |
| Beneficio Operativo | -$383996 | -$456865 | -$726604 | -$6.2M | -$18.7M | -$19.4M | -$15.7M | -$28.0M |
| EBITDA | -$69444 | -$450247 | -$1.9M | -$6.7M | -$17.5M | -$18.0M | -$16.2M | -$34.3M |
| Gastos por Intereses | 0 | $156965 | $394573 | $95070 | $17.6M | $55899 | $26813 | $6616 |
| Beneficio Antes de Impuestos | -$453440 | -$607212 | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.4M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $226068 |
| Beneficio Neto | -$453440 | -$607212 | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| BPA | $-2359.09 | $-72.00 | $-293.76 | $-648.00 | $-73187.37 | $-3453.65 | $-47.14 | $-52.59 |
| BPA Diluido | $-2359.09 | $-72.00 | $-293.76 | $-648.00 | $-1080.00 | $-3453.53 | $-47.14 | $-52.59 |
| Acciones en Circulación (Diluidas) | $192 | $6407 | $7979 | $10532 | $16221 | $5424 | $356115 | $689713 |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$4781 | 0 | -$23936 | -$23937 |
| Beneficio Operativo | -$4.6M | -$16.0M | -$7.3M | -$6.8M |
| EBITDA | -$4.8M | -$13.2M | -$17.5M | -$6.7M |
| Beneficio Neto | -$4.9M | -$13.4M | -$17.8M | -$6.7M |
| BPA | $-5.82 | $-16.42 | $-21.28 | $-7.17 |
| BPA Diluido | $-5.82 | $-16.42 | $-21.28 | $-7.17 |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $212979 | $204471 | $828016 | $20.8M | $5.0M | $2.8M | $5.8M | $17.8M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | $360229 | 0 | 0 | $3.3M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $214646 | $204471 | $831215 | $22.7M | $7.4M | $4.5M | $7.1M | $22.0M |
| Inmovilizado Material | 0 | 0 | 0 | $206268 | $208581 | $602401 | $89305 | $370681 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $25.7M |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $114.3M |
| Activos Totales | $214646 | $216743 | $1.1M | $22.9M | $7.6M | $5.2M | $7.3M | $162.4M |
| Cuentas por Pagar | 0 | $27257 | 0 | $2.0M | 0 | 0 | $2.6M | $3.1M |
| Deuda a Corto | $35685 | 0 | 0 | 0 | 0 | 0 | $38291 | 0 |
| Pasivos Corrientes | $117682 | $62942 | $404862 | $2.5M | $4.3M | $3.5M | $2.8M | $3.5M |
| Deuda a Largo | $436215 | $927810 | $2.1M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $718613 | $1.3M | $4.5M | $2.5M | $4.3M | $3.5M | $9.3M | $152.1M |
| Reservas | -$510777 | -$1.1M | -$3.5M | -$10.3M | -$27.9M | -$46.4M | -$63.2M | -$97.9M |
| Patrimonio Neto | -$503967 | -$1.1M | -$3.4M | $20.4M | $3.2M | $1.6M | -$2.0M | $10.3M |
| Deuda Total | $471900 | $927810 | $2.1M | 0 | 0 | $450571 | $38291 | 0 |
| Deuda Neta | $258921 | $723339 | $1.3M | -$20.8M | -$5.0M | -$2.3M | -$5.8M | -$17.8M |
| Capital Circulante | $96964 | $141529 | $426353 | $20.2M | $3.0M | $964848 | $4.3M | $18.5M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $2.8M | $17.8M | $12.8M | $8.4M |
| Activos Totales | $5.2M | $162.4M | $157.2M | $151.0M |
| Pasivos Totales | $3.8M | $152.1M | $12.6M | $12.7M |
| Patrimonio Neto | $1.4M | $10.3M | $144.5M | $138.4M |
| Deuda Total | 0 | 0 | 0 | $652411 |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$453440 | -$607212 | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| Amortizaciones | 0 | 0 | 0 | $42470 | $98606 | $516746 | $534857 | $114177 |
| Compensación en Acciones | $22379 | $1397 | $45444 | $185996 | $395329 | 0 | $1.7M | $485428 |
| Cambio en Capital Circulante | $24941 | -$4704 | $309763 | $432386 | $1.3M | -$1.1M | -$351479 | $15567 |
| Flujo de Caja Operativo | -$299572 | -$508508 | -$492971 | -$5.3M | -$15.8M | -$18.1M | -$13.3M | -$19.5M |
| Inversiones (CapEx) | 0 | 0 | 0 | -$254820 | -$100918 | -$35609 | -$21761 | -$6660 |
| Adquisiciones | 0 | 0 | 0 | $3000 | 0 | 0 | 0 | $2224 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$299572 | -$508508 | -$492971 | -$5.5M | -$15.9M | -$18.1M | -$13.4M | -$19.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$4.1M | -$8.1M | -$4.98B | -$5.4M |
| Inversiones (CapEx) | $3 | -$6660 | -$3 | 0 |
| Flujo de Caja Libre | -$4.1M | -$8.1M | -$4.98B | -$5.4M |
| Dividendos Pagados | 0 | 0 | -$1.73B | -$115000 |
| Compensación en Acciones | 0 | -$95.7M | 0 | 0 |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -33.9% | -286.0% | -192.0% | -156.7% | -5.6% | +9.7% | -106.9% |
| Crecimiento BPA (anual) | | +96.9% | -308.0% | -120.6% | -11194.3% | +95.3% | +98.6% | -11.6% |
| Cambio en Acciones (anual) | | +3233.3% | +24.5% | +32.0% | +54.0% | -66.6% | +6465.0% | +93.7% |
| Crecimiento FCF (anual) | | -69.7% | +3.1% | -1020.1% | -187.3% | -14.2% | +26.2% | -46.2% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.7% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-1558.57 | $-79.37 | $-61.78 | $-524.28 | $-977.96 | $-3338.63 | $-37.51 | $-28.31 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $192 | $6407 | $7979 | $10532 | $16221 | $5424 | $356115 | $689713 |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -58.08% |
| Rentabilidad sobre capital invertido | -23.73% |
| Rentabilidad sobre activos | -28.33% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 1.97 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.26 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -1160.30 | -38017.47 | -9318.01 | -2028.24 | -4.76 | -1.23 | -1.40 | -0.13 |
| P/VC | -1043.97 | -15979.44 | -6408.18 | 678.39 | 1743.07 | 14.10 | -11.66 | 0.46 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |